Trilipix

Compare the Global Sales of Blockbuster Drugs Losing Patent this Year (2014)

Posted on

Compare the global sales of 2013 and 2012 of the top ten blockbuster drugs which is losing patent this year. Teva Pharmaceutical’s Copaxone is the most affected drugs in terms of sales as the sales of 2013 has increased to 4.328 billions bearing the highest loss. Least affected Drug is AbbVie’s Trilipix which has faced the decrease in sales from 1.098 billions to 303 millions.

Blockbuster Drugs Global Sales 2012-13
Blockbuster Drugs Global Sales 2012-13

 

Table: Global Sales of Blockbuster Drugs for 2012 and 2013

Brand Name Global Sales 2012 USD (b) Global Sales 2013

USD (b)

Copaxone 3.996 4.328
Nexium 3.994 3.872
Micardis/Micardis HCT 2.217 0.97
Sandostatin LAR 1.512 1.589
Exforge/Exforge HCT 1.352 1.456
Nasonex 1.268 1.335
Trilipix 1.098 0.303
Evista 1.01 1.05
Renagel/Renvela 0.861 0.75
Restasis 0.792 0.94
Advertisements